Literature DB >> 15709016

MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Margaret Chen1, Christina Barnfield, Tanja I Näslund, Marina N Fleeton, Peter Liljeström.   

Abstract

While virus-infected dendritic cells (DCs) in certain instances have the capacity to activate naive T cells by direct priming, cross-priming by DCs via the uptake of antigens from infected cells has lately been recognized as another important pathway for the induction of antiviral immunity. During cross-priming, danger and stranger signals play important roles in modulating immune responses. Analogous to what has been shown for other microbial infections, virally infected cells may contain several pathogen-associated molecular patterns that are recognized by Toll-like receptors (TLRs). We analyzed whether the efficient presentation of antigens derived from infected cells requires the usage of MyD88, which is a common adaptor molecule used by all TLRs. For this study, we used murine DCs that were wild type or deficient in MyD88 expression and fibroblasts that were infected with an alphavirus replicon to answer this question. Our results show that when DCs are directly infected, they are able to activate antigen-specific CD8(+) T cells in a MyD88-independent manner. In contrast, a strict requirement of MyD88 for cross-priming was observed when virally infected cells were used as a source of antigen in vitro and in vivo. This indicates that the effects of innate immunity stimulation via the MyD88 pathway control the efficiency of cross-presentation, but not direct presentation or DC maturation, and have important implications in the development of cytotoxic T lymphocyte responses against alphaviral replicon infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709016      PMCID: PMC548467          DOI: 10.1128/JVI.79.5.2964-2972.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

Review 1.  Dendritic cells and viral immunity: friends or foes?

Authors:  D Kaiserlian; B Dubois
Journal:  Semin Immunol       Date:  2001-10       Impact factor: 11.130

Review 2.  Antigen presentation and T cell stimulation by dendritic cells.

Authors:  Pierre Guermonprez; Jenny Valladeau; Laurence Zitvogel; Clotilde Théry; Sebastian Amigorena
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

4.  Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation.

Authors:  Sibylle Mathys; Timm Schroeder; Joachim Ellwart; Ulrich H Koszinowski; Martin Messerle; Ursula Just
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

5.  Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells.

Authors:  Hanping Feng; Yi Zeng; Michael W Graner; Emmanuel Katsanis
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

6.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

7.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

8.  Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation.

Authors:  Tsuneyasu Kaisho; Katsuaki Hoshino; Tomio Iwabe; Osamu Takeuchi; Teruhito Yasui; Shizuo Akira
Journal:  Int Immunol       Date:  2002-07       Impact factor: 4.823

9.  Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells.

Authors:  Charles A Scanga; Julio Aliberti; Dragana Jankovic; Florence Tilloy; Soumaya Bennouna; Eric Y Denkers; Ruslan Medzhitov; Alan Sher
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 10.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

View more
  19 in total

1.  Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.

Authors:  Asa S Hidmark; Eva K L Nordström; Pia Dosenovic; Mattias N E Forsell; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Authors:  Norman Woller; Sarah Knocke; Bettina Mundt; Engin Gürlevik; Nina Strüver; Arnold Kloos; Bita Boozari; Peter Schache; Michael P Manns; Nisar P Malek; Tim Sparwasser; Lars Zender; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

3.  STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation.

Authors:  Jun Xu; Michael H Lee; Marita Chakhtoura; Benjamin L Green; Kevin P Kotredes; Robert W Chain; Uma Sriram; Ana M Gamero; Stefania Gallucci
Journal:  J Immunol       Date:  2016-05-27       Impact factor: 5.422

4.  Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

Authors:  Francesca Avogadri; Roberta Zappasodi; Arvin Yang; Sadna Budhu; Nicole Malandro; Daniel Hirschhorn-Cymerman; Shakuntala Tiwari; Maureen F Maughan; Robert Olmsted; Jedd D Wolchok; Taha Merghoub
Journal:  Cancer Immunol Res       Date:  2014-02-26       Impact factor: 11.151

5.  Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.

Authors:  Engin Gürlevik; Norman Woller; Nina Strüver; Peter Schache; Arnold Kloos; Michael P Manns; Lars Zender; Florian Kühnel; Stefan Kubicka
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

6.  The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Authors:  C Puig-Saus; E Laborda; A Rodríguez-García; M Cascalló; R Moreno; R Alemany
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

7.  Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Authors:  Francesca Avogadri; Taha Merghoub; Maureen F Maughan; Daniel Hirschhorn-Cymerman; John Morris; Erika Ritter; Robert Olmsted; Alan N Houghton; Jedd D Wolchok
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection.

Authors:  Adeeb H Rahman; Weiguo Cui; David F Larosa; Devon K Taylor; Jidong Zhang; Daniel R Goldstein; E John Wherry; Susan M Kaech; Laurence A Turka
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated parapoxvirus ovis.

Authors:  Sabine Siegemund; Andrea Hartl; Heiner von Buttlar; Franziska Dautel; Rüdiger Raue; Marina A Freudenberg; György Fejer; Mathias Büttner; Gabriele Köhler; Carsten J Kirschning; Tim Sparwasser; Gottfried Alber
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

10.  Myd88-dependent toll-like receptor 7 signaling mediates protection from severe Ross River virus-induced disease in mice.

Authors:  Lauren M Neighbours; Kristin Long; Alan C Whitmore; Mark T Heise
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.